Use of L-asparaginase in childhood ALL

Critical Reviews in Oncology/Hematology

Volumn 28, Issue 2, 1998, Pages 97-113

  Muller H J ^a   Boos, J ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; ASPARAGINASE; ASPARAGINASE MACROGOL; ASPARAGINASE MEDAC; CIDEROLASE; METHOTREXATE; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; BLOOD CLOTTING DISORDER; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHILD; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOGENICITY; INFANT; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; PANCREAS FUNCTION; PANCREATITIS; REVIEW;

ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE;

EID: 0032145202     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(98)00015-8     Document Type: Review

References (174)

1. Adamson RH, Fabro S Antitumor activity and other biologic properties of L-asparaginase (NSC-109229) - a review. Cancer Chemother Rep. 52:1968;617-626.
2. Ahlke E, Nowak-Göttl U, Schulze-Westhoff P et al. Dose reduction of asparaginase under pharmacokinetik and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Hematol. 96:1997;675-681.
3. Altenbern RA, Housewright RD Stereospecific asparaginases in smooth Brucella abortus strain 19. Arch Biochem Biophys. 49:1954;130-137.
4. Asselin B, Gelber R, Sallan S Relative toxicity of E. coli L-asparaginase (ASP) and PEGasparaginase (PEG) in newly diagnosed chidhood acute lymphoblastic leukemia (ALL). Med Pediatr Oncol. 21:1993;556.
5. Asselin BL, Whitin JC, Coppola DJ et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 11:1993;1780-1786.
6. Bauer KA, Teitel JM, Rosenberg D L-Asparaginase induced antithrombin III deficiency: Evidence against the production of a hypercoagulable state. Thromb Res. 29:1983;437-442.
7. Beard MEJ, Crowther D, Galton DAG et al. L-Asparaginase in treatment of acute leukemia and lymphosarcoma. Br Med J. 1:1970;191-195.
8. Becker FF, Broome JD L-Asparaginase: inhibition of endogenous RNA polymerase activity in regenerating liver. Arch Biochem Biophys. 130(1):1969;332-336.
9. Becker FF, Broome JD L-Asparaginase: inhibition of early mitosis in regenerating rat liver. Science. 156:1967;1602-1603.
10. Bertolone SJ, Fuenfer MM, Groff DB et al. Delayed pancreatic pseudocyst formations. Long-term complication of L-asparaginase treatment. Cancer. 50(12):1982;2964-2966.
11. Billett AL, Carls A, Gelber RD et al. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to E. coli asparaginase. Cancer. 70:1992;201-206.
12. Boch D Les cinditions d′action de l′asparaginase de l′Aspergillus niger. CR Soc Biol, Paris. 187:1928;955-956.
13. Boos J Pharmacokinetics and drug monitoring of L-asparaginase treatment. Int J Clin Pharm Ther. 35(3):1997;96-98.
14. Boos J, Jürgens H Pegaspargase (polyethylene glycol-L-asparaginase) - a viewpoint by Joachim Boos and Herbert Jürgens. Clin Immunother. 5(6):1996;497-498.
15. Boos J, Werber G, Ahlke E et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer. 32A(9):1996;1544-1550.
16. Boos J, Nowak-Göttl U, Jürgens H et al. Loss of activity of Erwinia asparaginase on repeat applications. J Clin Oncol. 13:1995;2474-2475.
17. Borsa J, Whitmore GF Cell killing studies on the mode of action of methotrexate on L-cells in vitro. Cancer Res. 29:1969;737-744.
18. Boyse EA, Old LJ, Campell HA et al. Suppression od murine leukemias of various types: comparative inhibitory activities of guinea pig serum L-asparaginase and E. coli L-asparaginase. J Exp Med. 125:1967;17-31.
19. Broome JD L-Asparaginase: discovery and development as a tumor-inhibitory agent. Cancer Treat Rep. 65 (Suppl 4):1981;111-114.
20. Broome JD Studies on the mechanism of tumor inhibition by L-asparaginase. J Exp Med. 127:1968;1055-1072.
21. Broome JD Factors which may influence the effectiveness of L-asparaginase as tumor inhibitors. Br J Cancer. 22:1968;595.
22. Broome JD Antilymphoma activity of L-asparaginase in vivo: clearance rates of enzyme preparations from guinea pig serum and yeast in relation to their effect on tumor growth. J Natl Cancer Inst. 35:1965;967-974.
23. Broome JD Evidence that the L-asparaginase of guinea pig serum is respnsible for its antilymhpoma effects and properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance. J Exp Med. 118:1963;99-120.
24. Brueck M, Koerholz D, Nuernberger W et al. Elimination of L-asparaginase in children treated for acute lymphoblastic leukemia. Dev Pharmacol Ther. 12:1989;200-204.
25. Bussolati O, Belletti S, Uggeri J et al. Characterization of apoptotic phenomena induced by treatment with L-asparaginase in NIH-3T3 cells. Exp Cell Res. 220:1995;283-291.
26. Butenandt I, Demus A, Versmold H Diabetic carbohydrate alterations during therapy of leukemia. Klin Wochenschr. 48:1970;1414-1417.
27. Cairo MS Adverse reactions of L-asparaginase. Am J Pediatr Hematol Oncol. 4:1982;335-339.
28. Campbell HA, Mashburn LT L-Asparaginase EC-2 from E. coli. Some substrate specificity characteristics. Biochemistry. 8(9):1969;3768-3775.
29. Campbell H, Mashburn L, Boyse E et al. Two L-asparaginases from E. coli B, their separation, purification and antitumor activity. Biochem Genet. 6:1967;721-730.
30. Capizzi RL, Cheng YC Therapy of neoplasia with asparaginase. Holcenberg J, Roberts J Enzymes as Drugs. 1981;1-24 Wiley, New York.
31. Capizzi RL Improvement in the therapeutic index of methotrexate (NSC 109229) by L-asparaginase (NSC 109299). Cancer Chem Rep. 6:1975;37-41.
32. Capizzi RL Schedule-dependent synergism and antagonism between methotrexate and L-asparaginase. Biochem Pharmacol. 23 (Suppl 2):1974;151-161.
33. Capizzi RL, Castro O, Aspnes G et al. Treatment of acute lymphocytic leukemia with intermittent high dose methotrexate and asparaginase. Proc Am Assoc Cancer Res ASCO. 15:1974;182.
34. Capizzi RL, Bertino JR, Skeel RT et al. L-Asparaginase: clinical, biochemichal, pharmacological and immunological studies. Ann Intern Med. 74:1971;893-901.
35. Carpentieri U, Balch MT Hyperglycemia associated with the therapeutic use of L-asparaginase: possible role of insulin receptors. J Pediatr. 93:1978;775-778.
36. Chambon JP, Dupriez B, Danjou P et al. Acute necrotic pancreatitis secondary to asparaginase. Role of drug combinations - early diagnosis and treatment. A proposal of two cases. J Chir Paris. 130(2):1993;74-78.
37. Cheung NKV, Chau IY, Coccia PF Antibody response to E. coli L-asparaginase: prognostic significance and clinical utility of antibody measurement. Am J Pediatr Hematol Oncol. 8(2):1986;99-104.
38. Clarkson B, Krakoff I, Burchenal J et al. Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma and solid tumors. Cancer. 25:1970;279-305.
39. Clementi A La désamidation enzymatique de l′asparaginase chez les différentes especes animales et la signification physiologique de sa présence dans l′organisme. Arch Intern Physiol. 19:1922;369-398.
40. Cooney D, Handschuhmacher R L-Asparaginase and L-asparagine metabolism. Ann Rev Pharmacol. 10:1970;421-440.
41. Cremer P, Lakomek M, Beck W et al. The effect of L-asparaginase on lipid metabolism during induction chemotherapy of childhood lymphoblastic leukaemia. Eur J Pediatr. 147:1988;64-67.
42. Dahlbäck B, Carlsson M, Svensson PJ Familial thrombophilia dur to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 90:1993;1004-1008.
43. DeGroot N, Lichtenstein N The action of Pseudomonas fluorescens extracts on asparagine and asparagine derivatives. Biochem Biophys Acta. 40:1960;99-110.
44. Dellinger CT, Miale TD Comparison of anaphylactic reactions to asparaginase derived from E. coli and from Erwinia cultures. Cancer. 38:1976;1843-1846.
45. DeMars R, Hooper LJ A method for selecting for auxotrophic mutants of HeLa cells. J Exp Med. 111:1960;559-571.
46. Desai S, Amylon M, Schwenn MR, et al. Outcome of advanced stage III-IV lymphoblastic non-Hodgkin's lymphoma - a Pediatric Oncology Group (POG) study. SIOP XXIX, 1997, Abstr O-140:356.
47. Dibenedetto SP, Di Cataldo A, Ragusa R et al. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia. J Clin Oncol. 13:1995;339-344.
48. Distasio J, Niedeman R, Kafkewitz D et al. Purification and characterization of L-asparaginase with anti-lymphoma activity from Vibrio succinogenes. J Biol Chem. 251:1976;6929-6932.
49. Dolowy WC, Henson D, Cornet J et al. Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia. Cancer. 19:1966;1813-1819.
50. Dox AW The intracellular enzymes of lower fungi, especially those of Penicillium camemberti. J Biol Chem. 6:1909;461-467.
51. Dübbers A, Schulze-Westhoff P, Kurzknabe E, et al. Asparagine synthetase in paediatric acute leukemias: a rationale to conduct a phase II trial with asparaginase in AML M5 subtype. SIOP XXIX, 1997, Abstr O-75:337.
52. Duncan R, Spreafico F Polymer conjugates - pharmacokinetic considerations for design and development. Clin Pharmacokinet. 27:1994;290-306.
53. Eden OB, Shaw MP, Lilleyman JS et al. Non-randomised study comparing toxicity of E. coli and Erwinia asparaginase in children with leukemia. Med Pediatr Oncol. 18:1990;497-502.
54. Errera M, Greenstein JP Desamidation of glutamine and asparagine in normal and neoplastic hepatic tisues. J Natl Cancer Inst. 7:1947;285-288.
55. Ertel IJ, Nesbit ME, Hammond D et al. Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from childrens cancer study group. Cancer Res. 39:1979;3893-3896.
56. Ettinger LJ, Ettinger AG, Avramis VI et al. Acute lymphoblastic leukemia - a guide to asparaginase and pegaspargase therapy. Biopharmaceuticals. 7(1):1997;30-39.
57. Evans WE, Tsiatis A, Rivera G et al. Anaphylactoid reactions to E. coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer. 49:1982;1378-1383.
58. Fabry U, Körholz D, Jürgens H et al. Anaphylaxis to L-asparaginase during treatment for acute lymphoblastic leukemia in children - evidence of a complement-mediated mechanism. Pediatr Res. 19:1985;400-408.
59. Fallet DV, Beardsley GP, Mikits T et al. Prolonged asparagine (ASN) depletion after high dose asparaginase (HDA) therapy in childhood acute lymphoblastic leukemia (ALL). Proc Annu Meet Am Assoc Cancer Res. 26:1985;156.
60. Falletta JM, Steuber CP, Hayes JW et al. Nonketotic hyperglycemia due to prednisone (NSC 10023) following ketotic hyperglycemia due to L-asparaginase (NSC 109299) plus prednisone. Cancer Chemother Rep. 56(1):1972;781-782.
61. Frankel SR, Kurtzberg J, DeOleivera D, et al. Toxicity and pharmacokinetics of PEG-asparaginase (PEG-asp) in newly diagnosed adult acute lymphoblastic leukemia (ALL): CALGB 9511. Blood 1996;88 (Suppl. 1/1):669a.
62. Furth O, Friedman M Über die Verbreitung asparaginspaltender Organfermente. Biochem Z. 26:1910;435-440.
63. Gentili D, Conter V, Rizzari C et al. L-Asparagine depletion in plasma and cerebrospinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia asparaginase. Ann Oncol. 7:1996;725-730.
64. Gialani S, Nussbaum A, Ohnuma T et al. Diabetes in patients treated with asparaginase. Clin Pharmacol Ther. 12:1971;487-490.
65. Gillette PC, Hill LL, Starling KA et al. Transient Diabetes mellitus secondary to L-asparaginase therapy in acute leukemia. J Pediatr. 81:1972;109-111.
66. Gorr G, Wagner J Über das Amidspaltungsvermögen der Hefen. Biochem Z. 254:1932;1-4.
67. Gralnik HR, Henry PH L-Asparaginase induced coagulopathy. Proc Am Assoc Cancer Res. 10:1969;32.
68. Greenstein JP, Carter CE Influences of α-keto acids on the desamination of amino acid amides. J Natl Cancer Inst. 7:1946;57-60.
69. Grover CE, Chibnall AC The enzymic deamination of asparagine in the higher plants. Biochem J. 21:1927;857-868.
70. Gugliotta L, Mazzucconi MG, Leone G et al. L-Asparaginase and haemostasis: a Gimema retrospective study on the incidence of thrombosis and haemorrhage in ALL patients. Thromb Haemost. 65:1991;1021.
71. Haley EE, Fischer GA, Welch AD The requirement for L-asparagine of mouse leukemia cells L5178Y in culture. Cancer Res. 21:1961;532-536.
72. Hall JG The partitioning of L-asparaginase betweeen blood and lymph. Recent Results Cancer Res. 33:1970;75-80.
73. Halpern YS, Grossowicz N Hydrolysis of amides by extracts from mycobacteria. Biochem J. 65:1957;716-720.
74. Harris RE, McCallister JA, Provisor DS et al. Methotrexate/L-asparaginase combination chemotherapy for patients with acute leukemia in relapse: a study of 36 children. Cancer. 46:1980;2004-2008.
75. Haskell CM, Canellos GP, Leventhal BG et al. L-Asparaginase: therapeutic and toxic effects in patients with neoplastic disease. New Engl J Med. 281:1969;1028-1034.
76. Hill JM, Roberts J, Loeb E et al. L-Asparaginase therapy for leukemia and other malignant neoplasms. J Am Med Assoc. 202:1967;882-888.
77. Ho D, Thetford B, Carter C et al. Clinical pharmacologic studies of L-asparaginase. Clin Pharmacol Therapeut. 11:1970;408-417.
78. Ho DHW, Yap HJ, Brown N et al. Clinical pharmacology of intramuscularly administered L-asparaginase. J Clin Pharm. 21:1981;72-78.
79. Holcenberg JS, Roberts J Enzymes as drugs. Annu Rev Pharmacol Toxicol. 17:1977;97-116.
80. Holland J, Fasanello S, Ohnuma T Psychiatric symptoms associated with L-asparaginase administration. J Psychiatr Res. 10:1974;105-113.
81. Hoogerbrugge N, Jansen H, Hoogerbrugge PM Transient hyperlipidemia during treatment of ALL with L-asparaginase is related to decreased lipoprotein lipase activity. Leukemia. 11(8):1997;1377-1379.
82. Jacquillat C, Weil M, Bussell A et al. Treatment of acute leukemia with L-asparaginase preliminary results on 84 cases. Recent Results Cancer Res. 33:1970;263-277.
83. Jaffe N, Traggis D, Das L et al. Favorable remission induction rate with twice weekly doses of L-asparaginase. Cancer Res. 33:1973;1-4.
84. Jaffe N Diabetes mellitus secondary to L-asparaginase therapy. J Pediatr. 81:1972;1220-1221.
85. Jaffe N, Traggis D, Das L et al. L-Asparaginase in the treatment of neoplastic diseases in children. Cancer Res. 31:1971;942-949.
86. Johnston PGB, Hardisty RM, Kay HEM et al. Myelosuppressive effect of colaspase (L-asparaginase) in initial treatment of acute lymphoblastic leukaemia. Br Med J. 3:1974;81-83.
87. Jones B, Holland JF, Glidewell O et al. Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia. Med Pediatr Oncol. 3:1977;387-400.
88. Kamisaki Y, Wada H, Yagura T et al. Reduction in immunogenicity and clearance rate of E. coli L-asparaginase by modification with monomethoxypolyethylene glycol. J Pharmacol Exp Ther. 216:1981;410-414.
89. Kidd JG Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum - course of transplanted cancers of various kinds in mice and rats given guinea pig serum or rabbit serum. J Exp Med. 98:1953;565-582.
90. Killander D, Dohlwitz A, Engstedt L et al. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer. 37:1976;220-228.
91. Kim JH, Pérez AG, Djordjevic B Studies on unbalanced growth in synchronized HeLa cells. Cancer Res. 28:1968;2443-2447.
92. Körholz D, Urbanek R, Jobke A et al. Bildung spezifischer IgG-Antikörper unter L-asparaginasebehandlung. Monatsschr Kinderheilkd. 135:1987;325-328.
93. Kolarz G, Pietschmann H Leukocyte alterations during asparaginase therapy. Wien Med Wochenschr. 121:1971;196-199.
94. Land VJ, Sutow WW, Fernbach DJ et al. Toxicity of L-asparaginase in children with advanced leukemia. Cancer. 30:1972;339-347.
95. Lavine RL, Brodsky I, Garofano CD et al. The effect of E. coli L-asparaginase on oral glucose tolerance and insulin release in man. Diabetologia. 15:1978;113-116.
96. Leonard JV, Kay JDS. Acute encephalopathy and hyperammonaemia complicating treatment of acute lymphoblastic leukaemia with asparaginase. Lancet 1986;i:162-3.
97. Lieberman MW, Verbin RS, Landay M et al. A probable role for protein synthesis in intestinal epithelial cell damage induced in vivo by cytosine arabinoside, nitrogen mustard or X-irradiation. Cancer Res. 30:1970;942-951.
98. Lobel JS, O′Brien RT, McIntosh S et al. Methotrexate and asparaginase combination chemotherapy in refractory acute lymphoblastic leukemia of childhood. Cancer. 43:1979;1089-1094.
99. Loos M, Borsos T Inactivation of complement by L-asparaginase not correlated with enzyme content. Nat New Biol. 237(71):1972;55-57.
100. Manning GB, Campbell LL Jr The asparagine deaminase of Bacillus coagulans and Bacillus stearothermophilus. Can J Microbiol. 3:1957;1001-1009.
101. Martin DS Combination versus single drug therapy. Cancer Chemother Rep. 10:1969;57-59.
102. Mashburn LT, Wriston JC Tumor inhibitory effect from E. coli. Arch Biochem Biophys. 105:1964;450-452.
103. Mathé G, Amiel JL, Clarysse A et al. The place of the L-asparaginase in the treatment of acute leukemia. Recent Results Cancer Res. 33:1970;279-287.
104. McLean R, Martin S, Lam PRL. Fatal case of L-asparaginase induced pancreatitis. Lancet 1982;ii:1401-2.
105. Miller HK, Salser JS, Balis ME Amino acid levels following L-asparagine amidohydrolase (EC.3.5.1.1.) therapy. Cancer Res. 29:1969;183-187.
106. Mitchell L, Hoogendoorn H, Giles AR et al. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L-asparaginase-induced antithrombin III deficiency. Blood. 83(2):1994;386-391.
107. Moure JMB, Whitecar JP Jr, Bodey JP Electroencephalogram changes secondary to asparaginase. Arch Neurol. 23:1970;365-368.
108. Nagura E, Kimura K, Yamada K et al. Nationwide randomized comparative study of doxorubucin, vincristine and prednisolone combination therapy with and without L-asparaginase for adult acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 33:1994;359-365.
109. Nakamura N, Morikawa Y, Tanaka M L-Asparaginase from E. coli. Part II: substrate sprecificity studies. Agric Biol Chem. 35(5):1971;743-751.
110. Nesbit ME, Ertel I, Hammond GD L-Asparaginase as a single agent in acute lymphocytic leukemia: survey of studies from childrens cancer study group. Cancer Treat Rep. 65 (Suppl 4):1981;101-107.
111. Nesbit M, Chard R, Evans A et al. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol. 1(1):1979;120-124.
112. Nesbit M, Chard R, Ertel I et al. Reduction of sensitivity reactions produced by L-asparaginase by combination with 6-mercaptopurine. Proc Am Assoc Cancer Res. 11:1971;39.
113. Neuman RE, McCoy TA Dual requirement of Walker carcinosarcoma 256 in vitro for asparagine and glutamine. Science. 124:1956;124-125.
114. Nowak-Göttl U, Schneider C, Schwabe D, et al. Defects in the protein C anticoagulant pathway and further risks of thrombophilia - first results of the German multicenter study on thromboembolism in childhood ALL. Blood 1997;90(10):72a (Suppl 1/1, Abstr 311).
115. Nowak-Göttl U, Ahlke E, Schulze-Westhoff P et al. Changes in coagulation and fibrinolysis in childhood ALL: a two-step dose reduction of one E. coli asparaginase preparation. Br J Haematol. 95:1996;123-126.
116. Nowak-Göttl U, Erben M, Münstermann G et al. Epithelial vWf and t-PA release after incubation with different concentrations of asparaginase and dexamethasone. Fibrinolysis. 10(2):1996;55-56.
117. Nowak-Göttl U, Schneider C, Schwabe D et al. Resistance to activated protein C (APCR) in children with acute lymphoblastic leukemia - the need for a prospective multicentre study. Blood Coagul Fibriniloysis. 6:1995;761-764.
118. Nowak-Göttl U, Wolff JEA, Kuhn N et al. Enhanced thrombin generation, P-von Willebrand factor, P-fibrin D-dimer and P-plasminogen activator inhibitor 1: predictive for venous thrombosis in asparaginase-treated children. Fibrinolysis. 8 (Suppl 2):1994;63-65.
119. Oettgen HF, Stephenson PA, Schwartz MK et al. Toxicity of E. coli L-asparaginase in man. Cancer. 25:1970;253-278.
120. Oettgen HF, Old LJ, Boyse EA et al. Inhibition of leukemias in man by L-asparaginase. Cancer Res. 27:1967;2619-2631.
121. Ohnuma T, Holland JF, Meyer P Erwinia carotorova asparaginase in patients with prior anaphylaxis to asparaginase from E. coli. Cancer. 30:1972;376-381.
122. Ohnuma T, Rosner F, Levy RN et al. Treatment of adult leukemia with L-asparaginase (NSC 109229). Cancer Chemother Rep. 55:1971;269-275.
123. Ohnuma T, Holland JF, Freeman A Biochemical and pharmacological studies with asparaginase in man. Cancer Res. 30:1970;2297-2305.
124. Ohnuma T, Holland JF, Nagal G et al. Effects of L-asparaginase in acute myelocytic leukemia. J Am Med Assoc. 210:1969;1919-1921.
125. Ortega JA, Nesbit ME, Donaldson MH L-Asparaginase, vincristine and prednisone for induction of first remission in acute lymphocytic leukemia. Cancer Res. 37:1977;535-540.
126. Otten J, Suciu S, Lutz P, et al. The importance of L-asparaginase (A'ase) in the treatment of acute lymphoblastic leukemia (ALL) in children: Results of the EORTC 58881 randomized phase III trial showing greater efficiency of E. coli (E. coli) as compared to Erwinia (Erw) A'ase. Blood 1996;88 (Suppl 1/1):669a.
127. Ouais SG The effect of L-asparaginase on carbohydrate metabolism. Fed Proc. 29:1970;831.
128. Pacquement H, Philippe N, Mechinaud F, et al. Importance of L-asparaginase (ASP), detrimental effects of additional cytosine-arabinoside (ARA-C) and of iv 6-mercaptopurine (6-MP) in the treatment of lymphoblastic non-Hodgkin lymphoma (LB-NHL): results of the EORTC 58881 randomized trial. SIOP XXIX, 1997, Abstr P-160:429.
129. Parsons SK, Skapek SX, Neufeld EJ et al. Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood. 6:1997;1886-1895.
130. Patel SS, Benfield P Pegaspargase (polyethylene glycol-L-asparaginase). Clin Immunother. 5(6):1996;492-496.
131. Pratt CB, Choi SI, Holton CP Low-dosage asparaginase treatment of children acute lymphocytic leukemia. Am J Dis Child. 121:1971;406-409.
132. Pratt CB, Simone JV, Zee P et al. Comparison of daily versus weekly L-asparaginase for the treatment of childhood acute leukemia. J Pediatr. 77:1970;474-483.
133. Pui CH, Chesney CM, Weed J et al. Altered von Willbrand factor molecule in children with thrombosis following asparaginase-prednisone-vincristine therapy for leukemia. J Clin Oncol. 3:1985;1266-1272.
134. Pui CH, Burghen GA, Bowman WP et al. Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone. J Pediatr. 99:1981;46-49.
135. Rao SP, Castells S Hypergluconemia in L-asparaginase induced diabetes mellitus. Am J Pediatr Hematol Oncol. 8:1986;83-85.
136. Reaman Gh, Steinherz PG, Gaynon PS, et al. Improved survival of infants less than 1 year of age with acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Cancer Treat Rep 1987;71:1033-8.
137. Riccardi R, Holcenberg JS, Glaubinger DL et al. L-Asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res. 41:1981;4554-4558.
138. Roberts J, Prager MD, Bachynsky N The antitumor activity of E. coli L-asparaginase. Cancer Res. 26:1966;2213-2217.
139. Rutler DA. Toxicity of asparaginase. Lancet 1975;i:1293-4.
140. Sadoff J, Hwang S, Rosenfeld D et al. Surgical pancreatic complications induced by L-asparaginase. J Pediatr Surg. 32(6):1997;860-863.
141. Saito M, Asakura H, Jokaji H et al. Changes in hemostatic and fibrinolytic proteins in patients receiving L-asparaginase therapy. Am J Hematol. 32:1989;20-23.
142. Sallan SE, Gelber RD, Kimball V et al. More is better! Update of Dana-Farber Cancer Institute/Childrens's Hospital acute lymphoblastic leukemia trials. Büchner T, Schellong G, Hiddemann W, Ritter J Acute Leukemias II: Haematology and Blood Transfusion. 1990;459-466 Springer-Verlag, Berlin.
143. Sallan SE, Hitchcock-Bryan S, Gelber R et al. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 43:1983;5601-5607.
144. Schwartz JH, Reeves JY, Broome JD Two L-asparaginases from E. coli and their action against tumors. Proc Natl Acad Sci USA. 56:1966;1516-1519.
145. Schwartz MK, Lash ED, Oettgen HF et al. L-Asparaginase activity in plasma and other biological fluids. Cancer. 25:1970;244-252.
146. Schwartz MK The distribution and clearance of L-asparaginase. Grundmann E, Oettgen HF Experimental and Clinical Effects of L-Asparaginase. 1970;58-63 Springer, Heidelberg.
147. Shaw MT, Barnes CC, Madden FJ, et al. L-Asparaginase and pancreatitis. Lancet 1970;ii:721.
148. Sobin LH, Kidd JG A metabolic difference between two lines of lymphoma 6C3HED cells in relation to asparaginase. Proc Soc Exp Biol Med. 119:1965;325-327.
149. Steenholt G On the distribution of asparaginase. Acta Physiol Scand. 8:1944;342-347.
150. Steinherz PG Transient, severe hyperlipidemia in patients with acute lymphoblastic leukemia treated with prednisone and asparaginase. Cancer. 74:1994;3234-3239.
151. Steuber CP, Levy GJ, Nix WL et al. Use of L-asparaginase and cytosine arabinoside for refractory acute lymphocytic leukemia with particular reference to T-cell leukemia. Med Pediatr Oncol. 5:1978;33-38.
152. Story MD, Voehringer DW, Stephens LC et al. L-Asparaginase kills lymphoma cells by apoptosis. Cancer Chemother Pharmacol. 32:1993;129-133.
153. Sur P, Fernandes DJ, Kut TE et al. L-Asparaginase-induced modulation of methotrexate polyglutamylation in murine leukemia L5178Y. Cancer Res. 47:1987;1313-1318.
154. Sutor AH, Niemeyer C, Sauter S et al. Gerinnungsveränderungen bei Behandlung mit den Protokollen ALL-BFM-90 und NHL-BFM-90. Klin Pädiatr. 204:1992;264-273.
155. Sutow WW, Garcia F, Starling KA et al. L-Asparaginase therapy in children with advanced leukemia. Cancer. 28:1971;819-824.
156. Tallal L, Tan C, Oettgen H et al. E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer. 25:1970;306-320.
157. Tan CL, Chang SP, Wee KP Acute hemorrhagic pancreatitis following L-asparaginase therapy in acute lymphoblastic leukemia - a case report. Singapore Med J. 15:1974;278-282.
158. Tsuji Y Amidase action of bacteria. Naika Hokan. 4:1957;222-224.
159. Wada H, Imamura I, Sako M et al. Antitumor enzyme: polyethylene glycol-modified asparaginase. Ann NY Acad Sci. 613:1990;95-108.
160. Wade HE, Robinson HK, Philips BW The asparaginase and glutaminase activities of microorganisms. J Gen Microbiol. 69:1971;299-332.
161. Wade HE, Elsworth R, Herbert E, et al. A new L-asparaginase with antitumor activity. Lancet 1968;ii:776-7.
162. Wahn V, Fabry U, Körholz D et al. Modified pharmacokinetics of L-asparaginase from E. coli by formation of specific antibodies to L-asparaginase of different immunoglobulin classes in children with acute lymphocytic leukemia. Pediatr Pharmacol. 3:1983;303-311.
163. Weetman RM, Baehner RL Latent onset of clinical pancreatitis in children receiving L-asparaginase therapy. Cancer. 34:1974;780-785.
164. Werber G, Ahlke E, Nowak-Göttl U, et al. Asparaginase activities in vitro are highly sensitive to different buffer conditions. In: Büchner et al., editors. Acute Leukemias VI - Prognostic Factors and Treatment Strategies. Berlin: Springer-Verlag, 1997:512-6.
165. Whelan H, Wriston H Purification and properties of asparaginase from E. coli B. Biochemistry. 8:1969;2386-2393.
166. Whitecar JP, Bodey GP, Harris JE et al. L-Asparaginase. New Engl J Med. 282:1970;732-735.
167. Wriston JJ Asparaginase. Methods Enzymol. 113:1985;608-618.
168. Wriston JC, Yellin TO L-Asparaginase: a review. Adv Enzymol Rel Areas Mol Biol. 39:1973;195-248.
169. Yap BS, Mc Credie KB, Keating MJ et al. Asparaginase and methotrexate combination chemotherapy in relapsed acute lymphoblastic leukemia in adults. Cancer Treat Rep. 65 (Suppl 1):1981;83-87.
170. Yasui I, Shimokawa T, Kasai M et al. A case of ALL complicated with acute pancreatitis and pancreatic pseudocyst caused by L-asparaginase. Gan To Kagaku Ryoho. 20(1):1993;149-152.
171. Yoshimoto T, Nishimura H, Saito Y et al. Characterization of polyethylene glycol-modified L-asparaginase from E. coli and its application to therapy in leukemia. Jap J Cancer Res (Gann). 77:1986;1264-1270.
172. Yu Ch, Lin KH, Lin DT, et al. L-Asparaginase-related pancreatic pseudocyst: report of a case. J Formos Med Assoc 1994;93(5):441-4.
173. Zubrod CG The clinical toxicities of L-asparaginase in the treatment of leukemia and lymphoma. Pediatrics. 45:1970;555-559.
174. Boos J et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer. 32A(9):1996;1544-1550.